The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Sanofi
Study ID
NCT07612878
Status
Recruiting
Apply to this trial

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cohort 1: Dupilumab — DRUG
    medicine already approved by the FDA
  • Cohort 2: usual care only — OTHER
    Usual care that patients receive

Study Details

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.

Key Dates

First listed
May 29, 2026
Start date
Aug 6, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2029
Completion
Nov 30, 2029

Study Design

Enrollment
350 participants (estimated)

Arms

  • Arm: Cohort 1: COPD participants prescribed dupilumab
    350 COPD consented participants prescribed dupilumab with prospective data collection
  • Arm: Cohort 2: Control COPD participants not prescribed dupilumab
    700 COPD control participants from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. These participants will not be consented with retrospective data collection.

Primary Outcome Measure

Participant Characteristics [ Time Frame: End of study (24 months after the last participant is enrolled) ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
IU Health Pulmonology & Critical Care MedicineIndianapolisIndiana46202
Kim McPeak
[email protected]
(317) 962-5820
Marc Rovner, MD, MMM, CPE, FACP, FCCP (PRINCIPAL_INVESTIGATOR)
DukeDurhamNorth Carolina27705
Jessica Shier
[email protected]
919-620-7300
Matt McCravy, MD (PRINCIPAL_INVESTIGATOR)
The Lung & Sleep Institute of North TexasNorth Richland HillsTexas76180
Neha Nair
[email protected]
817-284-9225
Tamer Hudali, MD MPH (PRINCIPAL_INVESTIGATOR)

Find similar trials in Indianapolis, IN

By research site
IU Health Pulmonology & Critical Care Medicine· Indianapolis, INDuke· Durham, NCThe Lung & Sleep Institute of North Texas· North Richland Hills, TX

Related Studies